Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart

Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the U.S. Food and Drug Administration, according to a City of Hope-led study. “This agent has shown in clinical trials to be effective in delaying cancer growth beyond established […]

Continue reading »

Genetic diversity facilitates cancer therapy

The constant battle against infectious pathogens has had a decisive influence on the human immune system over the course of our evolution. A key role in our adaptation to pathogens is played by HLA molecules. These proteins activate the immune system by presenting it with fragments of pathogens that have entered the body. People with a wide variety of different […]

Continue reading »

New gene therapy for epilepsy provides on-demand release of endogenous substance

Universitätsmedizin Berlin and the Medical University of Innsbruck have developed a new therapeutic concept for the treatment of temporal lobe epilepsy. It represents a gene therapy capable of suppressing seizures at their site of origin on demand. Having been shown to be effective in an animal model, the new method will now be optimized for clinical use. Results from this […]

Continue reading »

Novel regulator of mitochondrial cell death reveals a promising target for cancer therapy

Researchers at The Wistar Institute have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein could represent a promising therapeutic target. They also found that expression of MFF is regulated by Myc, a ubiquitous mediator of cell proliferation that contributes to development of many cancer types. These results were published online in […]

Continue reading »

Algorithm based on response, biology guides neuroblastoma therapy

(HealthDay)—Use of a response- and biology-based treatment algorithm for intermediate-risk neuroblastoma is associated with excellent survival and reduces treatment for some patients, according to a study published online Aug. 6 in the Journal of Clinical Oncology. Clare J. Twist, M.D., from the Roswell Park Cancer Institute in Buffalo, New York, and colleagues enrolled 404 evaluable patients between 2007 and 2011 […]

Continue reading »

MDM2 counteracts resistance to CDK4/6 inhibitors for melanoma therapy

A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, Ph.D., and Ann Richmond, Ph.D., has identified a possible second-line treatment for melanoma patients. The potential treatment would render CDK4/6 inhibitors, a class of drugs prescribed for some breast cancers, also effective against melanoma by combining the inhibitors with MDM2 compounds, which are […]

Continue reading »

Injectable ‘bone spackling’: A cell therapy approach to heal complex fractures

Large, complex bone wounds are hard for doctors and patients alike to contend with. They often require grafts and multiple surgeries. Jan Stegemann, a University of Michigan professor of biomedical engineering, is reprogramming adult cells from bone marrow so that they can be injected directly into a wound and grow into bone. The marrow-derived cells are known as progenitor cells, […]

Continue reading »

Smart brain stimulators: Next-gen parkinson’s disease therapy

Researchers at the University of Houston have found neuro biomarkers for Parkinson’s disease that can help create the next generation of “smart” deep brain stimulators, able to respond to specific needs of Parkinson’s disease patients. Those with the disease often undergo the high-frequency brain stimulation, a well-established therapy for the progressive nervous system disorder that affects movement, but the therapy […]

Continue reading »
1 2 3 6